Transparency in drug pricing sounds like a great idea, but a new study finds that almost none of the state laws provide real price insights.
For the second month in a row, AbbVie’s Humira, Gilead Sciences' Truvada and Allergan’s Botox topped pharma TV spending in that order.
Novartis is joining a group of drugmakers already advertising cancer treatments on TV with the launch of its Piqray campaign.
Novartis needs to trace its ethics woes to their roots and apply its stated values to real-life decisions, experts say. Even then, change takes time.
With Johnson & Johnson battling talc and opioid lawsuits and now a Risperdal verdict, is the brand facing a decline?
Welcome to OmegaTown, also known as Newport, Rhode Island. This summer, RB set up camp in the seaside fishing community to put omega-3s to the test.
Novo Nordisk is hooking up with new-wave weight loss program Noom to support people with obesity.
Rival PARP inhibitors by GSK and AstraZeneca-Merck already have their own NICE backing, though neither of the three is on routine coverage.
Novartis' Beovu will be going up against entrenched rivals with a couple blemishes in its label, analysts wrote.
Is AbbVie duplicating its Humira TV strategy with follow-up Skyrizi? With the first Skyrizi campaign, the Illinois company jumped quickly into TV ads.
